Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity Is Associated with Phosphorylation of Raptor by mTOR*

mTORC1 contains multiple proteins and plays a central role in cell growth and metabolism. Raptor (regulatory-associated protein of mammalian target of rapamycin (mTOR)), a constitutively binding protein of mTORC1, is essential for mTORC1 activity and critical for the regulation of mTORC1 activity in response to insulin signaling and nutrient and energy sufficiency. Herein we demonstrate that mTOR phosphorylates raptor in vitro and in vivo. The phosphorylated residues were identified by using phosphopeptide mapping and mutagenesis. The phosphorylation of raptor is stimulated by insulin and inhibited by rapamycin. Importantly, the site-directed mutation of raptor at one phosphorylation site, Ser863, reduced mTORC1 activity both in vitro and in vivo. Moreover, the Ser863 mutant prevented small GTP-binding protein Rheb from enhancing the phosphorylation of S6 kinase (S6K) in cells. Therefore, our findings indicate that mTOR-mediated raptor phosphorylation plays an important role on activation of mTORC1.

B (Akt/protein kinase B) (2) and protein kinase C (3,4). mTORC1 constitutively consists of mTOR, raptor, and mLst8/G␤L (1), whereas the proline-rich Akt substrate of 40 kDa (PRAS40) is a regulatory component of mTORC1 that disassociates after growth factor stimulation (5,6). Raptor is essential for mTORC1 activity by providing a substrate binding function (7) but also plays a regulatory role on mTORC1 with stimuli of growth factors and nutrients (8). In response to insulin, raptor binding to substrates is elevated through the release of the competitive inhibitor PRAS40 from mTORC1 (9, 10) because PRAS40 and the substrates of mTORC1 (4E-BP and S6K) appear to bind raptor through a consensus sequence, the TOR signaling (TOS) motif (10 -14). In response to amino acid sufficiency, raptor directly interacts with a heterodimer of Rag GTPases and promotes mTORC1 localization to the Rheb-containing vesicular compartment (15). mTORC1 integrates signaling pathways from growth factors, nutrients, energy, and stress, all of which generally converge on the tuberous sclerosis complex (TSC1-TSC2) through the phosphorylation of TSC2 (1). Growth factors inhibit the GTPase-activating protein activity of TSC2 toward the small GTPase Rheb via the PI3K/Akt pathway (16,17), whereas energy depletion activates TSC2 GTPase-activating protein activity by stimulating AMP-activated protein kinase (AMPK) (18). Rheb binds directly to mTOR, albeit with very low affinity (19), and upon charging with GTP, Rheb functions as an mTORC1 activator (6). mTORC1 complexes isolated from growth factor-stimulated cells show increased kinase activity yet do not contain detectable levels of associated Rheb. Therefore, how Rheb-GTP binding to mTOR leads to an increase in mTORC1 activity toward substrates, and what the role of raptor is in this activation is currently unknown. More recently, the AMPK and p90 ribosomal S6 kinase (RSK) have been reported to directly phosphorylate raptor and regulate mTORC1 activity. The phosphorylation of raptor directly by AMPK reduced mTORC1 activity, suggesting an alternative regulation mechanism independent of TSC2 in response to energy supply (20). RSKmediated raptor phosphorylation enhances mTORC1 activity and provides a mechanism whereby stress may activate mTORC1 independent of the PI3K/Akt pathway (21). Therefore, the phosphorylation status of raptor can be critical for the regulation of mTORC1 activity.
In this study, we investigated phosphorylation sites in raptor catalyzed by mTOR. Using two-dimensional phosphopeptide mapping, we found that Ser 863 and Ser 859 in raptor were phosphorylated by mTOR both in vivo and in vitro. mTORC1 activity in vitro and in vivo is associated with the phosphorylation of Ser 863 in raptor.

EXPERIMENTAL PROCEDURES
Materials-Antibodies to raptor (9), HA (9), and phosphospecific antibodies to the Thr 36 and Thr 45 sites (22) have been described previously. Phosphospecific antibodies to the Thr 389 site in S6K1 were from Cell Signaling Technology, Inc. FLAG antibodies were from Sigma-Aldrich. Recombinant human insulin (Novolin R) was from Novo Nordisk. Rapamycin was from Calbiochem-Novabiochem. Tween 20 was from Fisher, and Triton X-100 was from Sigma-Aldrich. L-1-Tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin was from Worthington. Cellulose TLC plates were from EMD Chemicals Inc.
Cell Culture, Treatment, and Extract Preparation-3T3-L1 adipocytes were differentiated as described previously (9) and were used in 10 -12 days. HEK293, HEK293E, and HEK293T cells were cultured in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum and used for transfection experiments. HEK293T cells were used to perform 32 P labeling and phosphopeptide mapping experiments. When compared with HEK293 and HEK293T cells, there are low basal levels of the phosphorylation of mTOR targets in HEK293E cells, and thus, HEK293E cells were used for insulin signaling studies. For amino acid starvation, the culture medium was replaced with a solution containing 145 mM NaCl, 5.4 mM KCl, 1.4 mM CaCl 2 , 1.4 mM MgSO 4 , 25 mM NaHCO 3 , 5 mM glucose, 0.2 mM sodium phosphate, and 10 mM HEPES, pH 7.4 for 1 h. To terminate the incubation, cells were rinsed once with chilled phosphate-buffered saline and then homogenized with a syringe with a 20-gauge needle in lysis buffer as described previously (9). Homogenates were centrifuged at 12,000 ϫ g for 10 min, and the supernatants were retained for analyses.
Transfection and Immunoprecipitation-Cells were seeded in 6-cm dishes or 6-well plates. 24 h later, plasmids were transfected using Lipofectamine 2000 (Invitrogen) at 1:1 ratio (w/v). The cells were harvested and analyzed at 36 h after transfection. Cell extracts were incubated with antibodies (2 g) bound to protein A-or G-agarose beads at 4°C for 2 h with constant mixing. The beads were then washed four times.
In Vitro Kinase Assay-As described (9), immune complex beads were rinsed with 1 ml of kinase buffer (50 mM NaCl, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 M microcystin LR, 10 mM HEPES, and 50 mM ␤-glycerophosphate, pH 7.4) and suspended in 60 l of kinase buffer. The kinase reactions were initiated by adding to 20 l of the suspension 5 l of kinase buffer supplemented with 0.5 mM [␥-32 P]ATP (PerkinElmer Life Sciences, 1,000 mCi/mmol), 50 mM MnCl 2 , and 0.25 g of 4E-BP1 as substrates or no substrate for the phosphorylation of raptor-mTOR complex. Reactions were terminated after 30 min at 30°C by adding SDS sample buffer. The relative amounts of 32 P incorporation were determined by phosphorimaging after SDS-PAGE.
In Vivo 32 P Radiolabeling and Two-dimensional Phosphopeptide Mapping-In vivo 32 P radiolabeling and two-dimensional phosphopeptide mapping were performed as described previously (23).

RESULTS AND DISCUSSION
Phosphorylation of Raptor by mTOR in Vitro-When conducting mTORC1 kinase assays in vitro with substrates such as 4E-BP1, S6K1, and PRAS40, we observed that both mTOR and raptor, isolated in the mTORC1 immune complex, also incorporated [␥-32 P]ATP. mTOR has been previously observed to undergo autophosphorylation at Ser 2481 (24). Therefore, we decided to investigate whether the phosphorylation of raptor is mediated by mTOR and to reveal, if possible, the functional consequences of raptor phosphorylation by mTOR. Triton X-100 causes disassociation of the mTOR-raptor complex, whereas nonionic detergents of Tween 20 do not (7,8). Therefore, cell extracts and immunoprecipitations were prepared in Tween 20 or Triton X-100 to isolate raptor immune complexes with or without mTOR. After incubation of the raptor immune complexes prepared in the presence of Tween 20 in vitro, raptor was phosphorylated, whereas incubation with [␥-32 P]ATP/Mn 2ϩ did not result in raptor phosphorylation when cell extracts were prepared with Triton X-100 (Fig. 1A). To confirm that the phosphorylation of raptor in vitro depends on mTOR activity, mTOR kinase dead (S2338A, KD) and constitutive active (deleting 2433-2451, ⌬RD) mutants were utilized in the mTORC1 kinase assay. With equal amounts of raptor recovered by mTOR, when compared with wild type, the mTOR KD mutant largely abolished kinase activity toward raptor, whereas mTOR ⌬RD substantially enhanced the phosphorylation of raptor (Fig. 1B). This suggests that the phosphorylation of raptor was dependent on mTOR kinase activity and inhibited by an intact regulatory domain of mTOR, as are the phosphorylations of mTORC1 substrates (4E-BP1, S6K1, and PRAS40). Of note, mTOR KD reduced the autophosphorylation of mTOR in vitro, but mTOR ⌬RD did not affect autophosphorylation (Fig. 1B). The mechanism by which the inhibitory domain of mTOR controls kinase activity is unknown. To investigate further,

FIGURE 1. Phosphorylation of raptor by mTOR in vitro.
A, FLAG-tagged raptor and Myc-tagged mTOR were co-expressed in HEK293T cells, and immunoprecipitation with antibody to FLAG tag was conducted in the presence of 0.2% Tween 20 (TW) or 0.2% Triton X-100 (TX). The immune complexes were mixed with [␥-32 P]ATP, and in vitro phosphorylation was performed. Autoradiography (Autorad) was visualized by phosphorimaging, and levels of mTOR and raptor were detected with immunoblots. B, mTOR wild type (wt), kinase dead (S2338A, KD), and constitutive active (deleting 2433-2451, ⌬RD) mutants were co-expressed with raptor in HEK293T cells. The mTOR-raptor complex was isolated by immunoprecipitation of FLAG-tagged mTOR, and then in vitro phosphorylation was performed by incubating with [␥-32 P]ATP. C, the mTOR-raptor immune complex was obtained as described in A with Tween 20. Washed immune complexes were incubated for 20 min with no additions (none) or the following: 10 M LY294002 (LY), 5 M rapamycin (rapa), 5 M GST-FKBP12 (BP12), or 5 M GST-FKBP12 plus 5 M rapamycin (rapaϩBP12), and then in vitro phosphorylation was measured by adding [␥-32 P]ATP.
we asked whether raptor phosphorylation is inhibited by rapamycin, the mTORC1-specific inhibitor. The mTORC1 immune complex was incubated with rapamycin and FKBP12. Incubating mTORC1 with rapamycin or FKBP12 alone was without effect on raptor phosphorylation; however, the combination of rapamycin and FKBP12 reduced the phosphorylation of raptor (Fig. 1C). Consistently, LY294002, which is also an inhibitor of PI3K/mTOR but by a different mechanism, abolished raptor phosphorylation as well. Taken together, the in vitro phosphorylation of raptor in mTORC1 is mediated by mTOR with similar characteristics as the other substrates of mTORC1 such as 4E-BP1, S6K1, and PRAS40.
Phosphorylation of Raptor by mTOR in Vivo Maps to Ser 859 and Ser 863 and Is Sensitive to Rapamycin-The phosphorylation of raptor in cells was studied by expressing raptor in HEK293T cells labeled with [ 32 P]orthophosphate. 32 P-labeled recombinant raptor was immunoprecipitated by FLAG tag antibody and resolved by SDS-PAGE. A 32 P-labeled raptor band with increased 32 P suitable for mapping was obtained by overexpression of raptor ( Fig. 2A). The raptor band was excised and digested by trypsin and then subjected to two-dimensional phosphopeptide mapping analysis. Raptor phosphorylated by mTOR in vitro, prepared as described in the legend for Fig. 1 (panel A), was digested by trypsin and mixed with raptor peptides phosphorylated in vivo to compare raptor phosphorylation sites catalyzed by mTOR in vitro with those obtained in vivo. The major phosphorylated peptides in vivo were obtained as indicated by spots of a-d and in vitro as indicated by spots of 1-5 (Fig. 2B). Phosphopeptides of b, c, and d from raptor phosphorylated in vivo co-migrated with spots of 1, 2, and 4 from in vitro mTOR-phosphorylated peptides (Fig. 2B, last panel), suggesting that these peptides (spots b, c, and d) could be phosphorylated by mTOR in vivo. We noticed that some peptides, such as spot 3 and 5, were phosphorylated by mTOR in vitro but were not present in the in vivo raptor phosphopeptide map. The additional phosphopeptides arising from the in vitro kinase reaction is not unusual and could be from several sources. In addition to kinases in vitro being more promiscuous than in vivo, it is also possible that the dephosphorylation of some sites occurs more rapidly in vivo. Alternatively, there could be a loss of some proteins during the immunoprecipitation of mTORC1 that could change the phosphorylation of raptor by mTOR in vitro when compared in vivo.
Mass spectrometry has become a powerful technology for phosphoproteomic studies, providing a starting point for biologic studies. Olsen et al. (25) defined a phosphoproteome in HeLa cells after stimulation of epidermal growth factor. In this phosphopeptide library (Ref. 25, document S2 in supplemental data) raptor phosphorylations at Ser 859 , Ser 863 , and Ser 884 were detected. We mutated these serine residues to alanine and tested whether they are phosphorylated in cells by using two-dimensional phosphopeptide mapping. As shown in Fig. 2C, Ser 863 and Ser 859 were phosphorylated in vivo because the mutations of Ser to Ala at 863 and 859 eliminated phosphopeptides represented at spots b and c. Interestingly, mutation of Ser 863 to Ala (S863A) caused the disappearance of both spot b and spot c, whereas mutation of Ser 859 to Ala (S859A) only eliminated spot c (Fig. 2C). Because Ser 859 and Ser 863 reside in the same tryptic peptide of 850 VLDTSSLTQSAPASPTNK 868 , the spot b and spot c likely represent different phosphorylation patterns within this single peptide. Spot c migrated slower in the first dimension and was less hydrophobic in the second dimension than spot b, suggesting that spot c has more phosphorylation than spot b. Thus, spot c represents the phosphorylation of both Ser 863 and Ser 859 , and spot b represents a single phosphorylation. As only S863A but not S859A caused the disappearance of spot b, spot b most likely represents phosphorylation at Ser 863 . This suggests that Ser 859 is phosphorylated only when Ser 863 is phosphorylated first. The phosphopeptide mapping of mutation at Ser 884 (S884A) remained unaltered when compared with wild type (Fig. 2C). Furthermore, we mutated Ser 863 to Glu and Thr. As predicted, mutation of Ser 863 to Glu eliminated phosphorylation at this site similar to the Ala mutant (supplemental Fig. S1A). Because in vitro mTORC1-mediated raptor phosphopeptides co-migrated with in vivo phosphopeptides containing Ser 863 and Ser 859 (spot 1 3 b and spot 2 3  c, Fig. 2B) and mutations of Ser 863 and Ser 859 to Ala eliminated spot 1 and 2 (data not shown), mTOR phosphorylates raptor at Ser 863 and Ser 859 in vitro as well. We next investigated whether the phosphorylation of Ser 863 and Ser 859 were regulated by growth factor A, FLAG-tagged raptor were transfected together with mTOR in HEK293T cells, and cells were labeled with [ 32 P]orthophosphate for 3 h followed by insulin treatment (200 nM) for 30 min. 32 P-labeled raptor (indicated by arrow) was immunoprecipitated (IP) with FLAG antibody and visualized by phosphorimaging after SDS-PAGE when compared with the control of immunoprecipitation of cell extract without FLAG-raptor expression. B, 32 P-labeled raptor phosphorylated by mTOR in vitro was prepared as described in the legend for Fig. 1 (for panel  A). The in vivo and in vitro 32 P-labeled raptor was excised and digested by trypsin. The trypsin-digested peptides of raptor phosphorylated in vivo, in vitro, and in a mixture of in vivo and in vitro (in vivoϩin vitro) were resolved by two-dimensional phosphopeptide mapping with electrophoresis at pH 1.9 (pH 1.9) as the first dimension and chromatography as the second dimension (chromato). Major peptide spots are indicated by a-d (in vivo), 1-5 (in vitro), and a-d, 1-5 (co-migration). C, raptor wild type (wt) and mutants of Ser to Ala at 859, 863, and 884 (S859A, S863A, and S884A) were used for two-dimensional phosphopeptide mapping. D, 3T3-L1 adipocytes were labeled with [ 32 P]orthophosphate for 3 h and treated without or with rapamycin (20 nM) for 20 min before insulin treatment (20 nM) for 30 min. Antibodies toward raptor were used to immunoprecipitate endogenous raptor complex. The trypsin-digested phosphopeptide maps of 32 P-labeled raptor were analyzed. The major phosphopeptides are indicated as a-c, and the densities of the spots were quantified from three experiments (mean Ϯ S.E. (error bars)) and expressed as the percentage of the density of spot a. Con, control; Ins, insulin; Insϩrapa, insulin plus rapamycin. stimulation and rapamycin. Because they have a low level of signaling and a robust response to insulin, 3T3-L1 adipocytes were utilized to analyze inducible raptor phosphorylation. After cells were labeled by [ 32 P]orthophosphate, the mTORC1 complex was immunoprecipitated with raptor antibodies. In multiple experiments, the phosphorylation of the peptide represented in spot a appeared not to be affected by insulin and rapamycin treatments. In response to insulin stimulation, the phosphorylation of Ser 863 and Ser 859 , represented in spot b and c, increased as a ratio when compared with spot a, and rapamycin treatment prior to insulin stimulation reduced the insulin-induced phosphorylation of Ser 863 and Ser 859 (Fig. 2D). Taking the phosphorylation of Ser 863 and Ser 859 by mTOR directly in vitro and their inhibition by rapamycin in vivo together, our data demonstrate that the phosphorylation of Ser 863 and Ser 859 is mediated by mTOR.
When comparing the sequences of phosphorylation sites catalyzed by mTORC1 (4E-BP1, S6K1, and PRAS40) and sites catalyzed by mTORC2 (Akt1 and protein kinase C-␣), there is not a high degree of selectivity (supplemental Fig. S1B). This may arise from the fact that the substrate specificity is largely dependent on the specific companion proteins of the complex (raptor for mTORC1 and rictor and SIN1 for mTORC2). For mTORC1, raptor binds to substrates, and the substrate specificity is mediated through the TOS motif within the substrates themselves (10 -14). However, the phosphorylation sites characterized as catalyzed by mTOR have two distinct categories: sites directed by proline at ϩ1 or ϩ2 such as Thr 36 , Thr 45 , Thr 69 , and Ser 64 in 4E-BP1, Ser 183 in PRAS40, Ser 450 in Akt1, and Ser 637 in protein kinase C-␣ and sites with surrounding hydrophobic residues such as Thr 389 in S6K1, Ser 473 in Akt1, and Ser 656 in protein kinase C-␣. Ser 863 and Ser 859 in raptor both contain a proline at ϩ1/ϩ2, similar to the mTORC1-mediated phosphorylation sites found in the 4E-BPs and PRAS40. Further comparing the proline-directed phosphorylation sites catalyzed by mTOR reveals that the Ϫ3 position shows a bias for hydrophobic residues.
Phosphorylation of Raptor at Ser 863 Regulates mTORC1 Activity-To determine whether phosphorylations of raptor modulate mTOR function, mTORC1 activity in vitro and in vivo were compared for cells co-expressing mTOR with raptor versus mutants (S859A, S863A, and S884A). mTORC1 immune complexes were isolated by immunoprecipitation of raptor with FLAG antibody. The mTORC1 activity in vitro was measured with 4E-BP1 as substrate. When compared with wild type raptor, the mutation of Ser 863 , but not Ser 884 , substantially reduced the phosphorylation of 4E-BP1 catalyzed by mTORC1 in vitro (Fig. 3A). The mutation of Ser 859 alone did not produce a significant decrease of mTORC1 activity. Because activation of mTORC1 activity is associated with an increase of 4E-BP1 binding to raptor (9), we examined 4E-BP1 binding to raptor phosphorylation mutants by using recombinant 4E-BP1 coupled to CNBr-activated Sepharose. As shown in supplemental Fig. S2A, the raptor mutants of S859A, S863A, and S884A did not produce a significant change in binding to 4E-BP1 when compared with raptor wild type. This indicates that raptor phosphorylationdoesnotaffect4E-BP1bindingtoraptorandthatthe mechanism by which the phosphorylation of raptor promotes mTORC1 activity is not due to an increase in substrate binding.
To measure the in vivo kinase activity of the expressed mTORC1, the mTOR rapamycin-resistant mutant (S2035W) was utilized, and endogenous mTORC1 activity was inhibited by rapamycin pretreatment. The mutant mTOR S2035W and S6K1 were expressed together with either raptor wild type or mutants in HEK293E cells, treated with rapamycin to block endogenous mTORC1 kinase activity, and then stimulated with insulin. Consistent with the mTORC1 activity in vitro, mutation of Ser 863 to Ala decreased insulin-stimulated mTORC1 activity in vivo as shown by decreased phosphorylation of S6K at Thr 389 (Fig. 3B), whereas mutation of Ser 859 and Ser 884 did not alter the phosphorylation of S6K at Thr 389 . Interestingly, when compared with the Ala mutant, mutation of Ser 863 to Glu appears to mimic phosphorylation, asseenintherecoveryofmTORC1activitytowardS6KatThr 389 after insulin treatment (supplemental Fig. S2B). However, we did not observe that the Ser-Glu mutant lead to increased basal mTORC1 activity (supplemental Fig. S2B). We discuss this in the below.
Because overexpression of GTP-binding protein Rheb promotes mTORC1 activity (19), we tested whether the activation of mTORC1 by Rheb requires raptor phosphorylation. Rheb was coexpressed with rapamycin-resistant mTOR, raptor, and S6K1, and background of endogenous mTORC1 activity was knocked down with rapamycin pretreatment. Overexpression of Rheb enhanced the phosphorylation of S6K1 at Thr 389 , as expected. However, expression of raptor containing the Ala mutation at Ser 863 , but not Ser 859 and Ser 884 , reduced the phosphorylation of S6K at Thr 389 activated by Rheb expression (Fig. 3C, left panel). As reported before (19), overexpression of Rheb overcomes the inhibition of the phosphorylation of S6K1 by amino acid depletion in cell culture medium. When Rheb was overexpressed with raptor wild type and mutants and amino acids were withdrawn from the cell culture medium, the raptor Ser 863 to Ala mutant suppressed the Rheb-mediated rescue of S6K1 phosphorylation (Fig. 3C, right panel).
Therefore, the phosphorylation of raptor at Ser 863 appears to be associated with mTORC1 activity and plays a critical role on the activation of mTORC1 in response to insulin. We propose that in response to growth factors, Rheb provides an initial stimulation of mTOR kinase activity, and the activation of mTOR results in raptor phosphorylation at Ser 863 and Ser 859 . Consequently, as an essential component of mTORC1, raptor phosphorylation leads to a stable activation of mTORC1 kinase activity toward downstream substrates such as S6K1 and 4E-BP1. It is possible that Rheb binding to mTOR initiates a conformational change in the mTOR complex. The subsequent phosphorylation of Ser 863 stabilizes the proposed Rheb-mediated conformational change and leads to an activation of mTORC1 kinase activity that persists in the absence of Rheb association. However, merely mimicking phosphorylation at Ser 863 by mutation to Glu is insufficient to initiate a conformational change in the absence of Rheb. Thus, in vivo the mutation of Ser 863 to Glu does not increase basal mTORC1 kinase activity in the absence of Rheb activation. In addition, mTORC1 regulation consists of several relatively separate mechanisms. Raptor phosphorylation may modulate an increase in mTOR kinase activity toward substrates that have been bound by raptor, whereas substrate binding to raptor, which is essentially regulated by PRAS40 in response to insulin (10), is independent of raptor phosphorylation.
According to raptor phosphopeptide mapping analysis, mutation of Ser 863 prevents the phosphorylation of both Ser 863 and Ser 859 . It is possible that mTORC1 activity needs phosphorylation at both sites. Recently, Ser 722 and Ser 792 in raptor were identified as AMPK-mediated phosphorylation sites and required for the inhibition of mTORC1 induced by energy stress (20), and Ser 719 , Ser 721 , and Ser 722 are primary phosphorylation sites mediated by RSK, which are required for mTORC1 activation by mitogen stimulation (21). All these sites are located in the region between the N-terminal conserved region and the C-terminal seven WD repeats. The raptor C terminus tightly interacts with mTOR (8,26), and the N-terminal conserved region is suggested to bind to the TOS motif in substrates such as S6K1 and 4E-BP1 (27). Mutation of raptor at Ser 863 did not change raptor binding to 4E-BP1 as measured by interaction with 4E-BP1 recombinant protein-coupled beads. Similarly, RSKmediated phosphorylation does not change raptor interaction with 4E-BP1 (21). Therefore, although 4E-BP1 binding to raptor does increase after insulin-stimulated dissociation of PRAS40 (9, 10), this does not involve raptor phosphorylation. Rather, the phosphorylation of raptor may promote the access of substrates bound to raptor to the mTOR kinase active site, probably due to a conformational change in mTORC1. As shown in Fig. 3A, mutation of Ser 863 did not change raptor interaction with mTOR. However, because mTOR and raptor interactions are mediated by multiple sites, raptor phosphorylation mightcausedifferentdirectionalinteractionchangesandthusleadsto an undetectable association change in vitro. Finally, it cannot be excluded that the effects of raptor phosphorylation involve additional proteins or a phosphatase that modify mTORC1 activity. Because it contains several activity-modifying phosphorylation sites, the region between the N and C terminus in raptor is functionally important and worth further investigating.